Literature DB >> 135638

Reactivity of lymphocytes from primary neoplasms of lymphoid tissues.

J J Twomey, A H Laughter, S Lazar, C C Douglass.   

Abstract

Proliferative responses by blood and tumor lymphocytes to plant mitogens and allogeneic leukocyte antigens were tested concomitantly on 12 patients with Hodgkin's disease, 10 with chronic lymphocytic leukemia, and seven with non-Hodgkin's lymphomas. In 13 control studies, 3H-thymidine incorporation by blood and lymph node lymphocytes was brisk and, overall, comparable. With Hodgkin's disease, where extent of disease involvement and lymphocyte-depleted tumor histology were factors in the degree of responsiveness, incorporation was higher or at least comparable by tumor lymphocytes when compared with incorporation by autologous blood lymphocytes. Lymph node lymphocytes, especially with clinically stable disease, were more responsive than blood lymphocytes with chronic lymphocytic leukemia. Conversely, tumor lymphocytes were hyporesponsive compared with autologous blood lymphocytes with non-Hodgkin's lymphomas, where prognosis is usually less favorable than with chronic lymphocytic leukemia. Plasma from four out of 33 patients, although not lymphocytotoxic, inhibited lymphoproliferative responses.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 135638     DOI: 10.1002/1097-0142(197608)38:2<740::aid-cncr2820380217>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Lymphocyte counts and functions in arterial and venous splenic blood of patients with Hodgkin's disease. Evidence for elimination of spontaneously DNA synthesizing cells in the spleen.

Authors:  M Björkholm; G Holm; J Askergren; H Mellstedt
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

2.  Spectrum of immunodeficiencies with Hodgkin's disease.

Authors:  J J Twomey; A H Laughter; L Rice; R Ford
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

3.  Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis.

Authors:  C Wedelin; M Björkholm; G Holm; S Ogenstad; B Johansson; H Mellstedt
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

Review 4.  Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.

Authors:  Christoph Renner; Frank Stenner
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.